Emmaus Life Scie Stock Price, News & Analysis

Emmaus Life Sciences announced that Florida has approved the inclusion of Endari, its prescription-grade L-glutamine oral powder, on the Medicaid Preferred Drug List (PDL) starting April 1, 2022. This decision means Endari can be prescribed without prior authorization, streamlining access for patients suffering from sickle cell disease. Florida joins several other states in eliminating prior authorization for this medication. CEO Yutaka Niihara emphasized that this approval brings them closer to making Endari widely available to healthcare providers.

On March 23, 2022, Emmaus Life Sciences announced the U.A.E. Ministry of Health approved its marketing application for Endari®, a treatment for sickle cell disease. After a five-month review, Endari was previously available only on an early access basis. Emmaus estimates about 600 sickle cell patients reside in the U.A.E. and approximately 225,000 in the MENA region could benefit from the drug. The company aims to secure further approvals across Gulf Cooperation Council states, highlighting the significance of this market due to the higher prevalence of sickle cell disease compared to the U.S.

Emmaus Life Sciences (OTCQX: EMMA) announced that Yutaka Niihara, CEO, will present a company overview at the H.C. Wainwright BioConnect Conference from January 10-13, 2021. The presentation will be available on-demand starting at 7:00 a.m. Eastern Time on January 10, and can be accessed on Emmaus' website. Emmaus Life Sciences is a leader in treating sickle cell disease and markets the FDA-approved Endari^® (L-glutamine powder) for reducing complications related to this condition.

Emmaus Life Sciences (OTCQX: EMMA) announced positive transfusion data from a post-hoc analysis of its phase 3 clinical study of Endari, an L-glutamine oral powder for sickle cell disease (SCD). Presented at the 63rd ASH Annual Meeting, the study showed that patients on Endari required approximately 43% fewer units of red blood cells compared to those on placebo over 48 weeks. The multicenter trial included 230 patients, indicating that Endari significantly reduces pain crises and hospitalizations. This highlights its potential as a complementary therapy alongside hydroxyurea.

Emmaus Life Sciences (OTCQX: EMMA) announced that its CEO, Yutaka Niihara, will present live on VirtualInvestorConferences.com on December 16 at 12:30 PM ET. Investors can engage with the company during this interactive online event, which will also be archived for later viewing. Attendees are encouraged to pre-register and check their systems for a smooth experience. Emmaus Life Sciences specializes in treating sickle cell disease and markets FDA-approved Endari, aimed at reducing acute complications of the condition.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) announced that data on Endari®, its L-glutamine oral powder for sickle cell disease, will be presented at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. The study, titled 'The Evaluation of Transfusion Data from the Phase 3 Clinical Study of L-Glutamine in Sickle Cell Disease,' will be presented on December 13, 2021. Endari® has been approved since July 2017 and is marketed to reduce complications of sickle cell disease in patients aged 5 and older. For further information, visit Emmaus' website.

Emmaus Life Sciences (OTCQX: EMMA) reported Q3 2021 net revenues of $5.8 million, up 3% year-over-year but down 6% from Q2 2021. For the nine months ending September 30, 2021, revenues increased 4% to $17.6 million. Operating loss for Q3 2021 was $31,000, compared to $8,000 in Q3 2020, with a net loss of $3.2 million. The company expanded access to its sickle cell treatment, Endari, through a partnership with UpScript and entered an agreement with Asembia for provider support. Emmaus also submitted a marketing application for Endari in the UAE and secured a license for Kainos' IRAK4 inhibitor.

Emmaus Life Sciences (OTCQX: EMMA) announced a partnership with UpScript IP Holdings to enhance access to its sickle cell disease treatment, Endari®, through telehealth services. This initiative aims to allow patients to receive physician consultations and prescriptions from home, thereby reducing exposure to infections. Endari®, approved in July 2017, is designed for patients aged five and older to alleviate acute complications of sickle cell disease. The telehealth services are set to launch in the coming months, promising improved patient convenience and healthcare accessibility.

Emmaus Life Sciences (OTCQX: EMMA) announced a partnership with Asembia to enhance patient and provider support services for Endari®, its L-glutamine oral powder treatment for sickle cell disease. Asembia will streamline insurance authorization, benefits investigation, and co-pay assistance, aiming to improve access for patients. This collaboration is expected to boost the efficiency of delivery for Endari to individuals suffering from sickle cell disease. Emmaus continues to focus on innovative treatments while supporting the approximately 100,000 individuals in the U.S. living with this condition.